Key points from article :
Oisín Biotechnologies funding tops $9.5 million, with additional funding to support preclinical development of its platform and investigational therapy for kidney and other age-related diseases.
Oisín uses precise DNA-based interventions to clear senescent cells from the body.
Its proprietary SENSOlytics technology is a third-wave innovation that uses a novel proteo-lipid vehicle drug delivery.
Delivers non-integrating DNA plasmids to senescent cells to trigger cell death without causing harmful side effects.
Reduced senescent cell burden, extending lifespan by more than 20% in mice.
After a single treatment, senescent cell removal rates reached as high as 70%.
If receives regulatory approval, this promising restorative therapy could be available in years.
“If senescent, then kill. If not, then ignore. We have been able to write a computer program in DNA...based on if/then logic,” - Gary Hudson, Co-founder.
Expects the first readouts from its preclinical study in CKD later this year.
